PT630409E - Vectores nao oncovirais deficientes no empacotamento baseados no mpmv - Google Patents

Vectores nao oncovirais deficientes no empacotamento baseados no mpmv

Info

Publication number
PT630409E
PT630409E PT93905485T PT93905485T PT630409E PT 630409 E PT630409 E PT 630409E PT 93905485 T PT93905485 T PT 93905485T PT 93905485 T PT93905485 T PT 93905485T PT 630409 E PT630409 E PT 630409E
Authority
PT
Portugal
Prior art keywords
packaging
lentivirus
nucleotides
heterologous gene
oncoviral
Prior art date
Application number
PT93905485T
Other languages
English (en)
Inventor
Andrew Michael Lindsay Lever
Eric Hunter
Original Assignee
Syngenix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929204350A external-priority patent/GB9204350D0/en
Priority claimed from GB929208489A external-priority patent/GB9208489D0/en
Application filed by Syngenix Ltd filed Critical Syngenix Ltd
Publication of PT630409E publication Critical patent/PT630409E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Packages (AREA)
  • Packging For Living Organisms, Food Or Medicinal Products That Are Sensitive To Environmental Conditiond (AREA)
  • Auxiliary Devices For And Details Of Packaging Control (AREA)
  • Supplying Of Containers To The Packaging Station (AREA)
PT93905485T 1992-02-28 1993-03-01 Vectores nao oncovirais deficientes no empacotamento baseados no mpmv PT630409E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929204350A GB9204350D0 (en) 1992-02-28 1992-02-28 Dtv agents
GB929208489A GB9208489D0 (en) 1992-04-16 1992-04-16 Ctv agents
GB929219935A GB9219935D0 (en) 1992-04-16 1992-09-21 Ctv agents

Publications (1)

Publication Number Publication Date
PT630409E true PT630409E (pt) 2003-04-30

Family

ID=27266069

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93905485T PT630409E (pt) 1992-02-28 1993-03-01 Vectores nao oncovirais deficientes no empacotamento baseados no mpmv

Country Status (11)

Country Link
US (2) US5747307A (pt)
EP (2) EP1262554A3 (pt)
JP (2) JP3765103B2 (pt)
AT (1) ATE228569T1 (pt)
AU (1) AU671101B2 (pt)
CA (2) CA2557882C (pt)
DE (1) DE69332519T2 (pt)
DK (1) DK0630409T3 (pt)
ES (1) ES2187504T3 (pt)
PT (1) PT630409E (pt)
WO (1) WO1993017118A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2269175A (en) * 1992-07-31 1994-02-02 Imperial College Retroviral vectors
WO1995025806A2 (en) * 1994-03-24 1995-09-28 Syngenix Limited Packaging-deficient lentiviruses
US5714353A (en) * 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
GB9510272D0 (en) * 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
FR2747046B1 (fr) * 1996-04-05 1998-06-19 Univ Paris Curie Nouveaux vaccins issus de plasmovirus
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
CA2803417A1 (en) * 1998-11-13 2000-05-25 Gbp Ip, Llc Selection system for generating efficient packaging cells for lentiviral vectors
US6797512B1 (en) 1998-11-13 2004-09-28 Cell Genesys, Inc. Selection system for generating efficient packaging cells for lentiviral vectors
US6790657B1 (en) 1999-01-07 2004-09-14 The United States Of America As Represented By The Department Of Health And Human Services Lentivirus vector system
EP1849873B1 (en) * 1999-04-29 2011-10-12 Gbp Ip, Llc Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2000072886A1 (en) 1999-05-26 2000-12-07 Dana-Farber Cancer Institute, Inc. Episomally replicating lentiviral vectors
WO2002060490A1 (en) * 2001-01-31 2002-08-08 Duke University Retroviral vector
GB0108065D0 (en) * 2001-03-30 2001-05-23 Syngenix Ltd Viral vectors
US6808905B2 (en) * 2001-05-14 2004-10-26 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
ATE535260T1 (de) 2001-06-29 2011-12-15 Sloan Kettering Inst Cancer Vektor kodierend humanes globin-gen und seine verwendung bei der behandlung von hämoglobinopathien

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604114A (en) * 1986-05-20 1997-02-18 Dana-Farber Cancer Institute Cis-acting repression sequences, cis-acting antirepression sequences, vectors, methods of preparation and use
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
WO1991005860A1 (en) * 1989-10-16 1991-05-02 Whitehead Institute For Biomedical Research Non-infectious hiv-1 particles and uses therefor
US5861282A (en) * 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
WO1991019798A1 (en) * 1990-06-20 1991-12-26 Dana Farber Cancer Institute Vectors containing hiv packaging sequences, packaging defective hiv vectors, and uses thereof
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US6174666B1 (en) * 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA

Also Published As

Publication number Publication date
CA2557882A1 (en) 1993-09-02
CA2117607A1 (en) 1993-09-02
CA2557882C (en) 2010-05-18
JP3765103B2 (ja) 2006-04-12
JP2004000280A (ja) 2004-01-08
DE69332519D1 (de) 2003-01-09
DE69332519T2 (de) 2003-07-17
ES2187504T3 (es) 2003-06-16
AU671101B2 (en) 1996-08-15
ATE228569T1 (de) 2002-12-15
EP1262554A2 (en) 2002-12-04
JP3779966B2 (ja) 2006-05-31
JPH07504322A (ja) 1995-05-18
EP0630409B1 (en) 2002-11-27
EP0630409A1 (en) 1994-12-28
EP1262554A3 (en) 2007-08-29
US5747307A (en) 1998-05-05
DK0630409T3 (da) 2003-03-24
WO1993017118A2 (en) 1993-09-02
AU3639493A (en) 1993-09-13
WO1993017118A3 (en) 1993-10-14
US6294165B1 (en) 2001-09-25

Similar Documents

Publication Publication Date Title
PT630409E (pt) Vectores nao oncovirais deficientes no empacotamento baseados no mpmv
GB2331522B (en) Lentiviral vectors
DK651589A (da) Kartoffelknoldspecifik transkriptional regulation
IL60186A0 (en) Dna transfer vector,microorganisms transformed thereby and a method for cloning a dioxynucleotide sequence
CA2467801A1 (fr) Sequences nucleiques issues du genome de salmonella typhi, et leurs utilisations notamment pour le diagnostic in vitro de la presence de bacteries du genre salmonella dans les produits alimentaires
PT781343E (pt) Hibridos de vectores retrovirais e sua utilizacao para transferencia genetica
ATE78295T1 (de) Von t-dns abgeleitete vector.
EP0769553A4 (en) DNA FRAGMENT, RECOMBINANT VECTOR THAT CONTAINS IT AND METHOD FOR EXPRESSING FOREIGN GENES WITH ITS USE
ES8800985A1 (es) Procedimiento de preparar proteinas.
HUT68809A (en) Dna sequences for an amino acid transporter, plasmids, bacteria, yeasts and plants containing a transporter and their use
DE59109072D1 (de) Klonierung der N-Methylhydantoinase
ES8306176A1 (es) Procedimiento para la preparacion de un vector hibrido y la clonacion de adn-ajeno en organismos hospetantes.
ATE133709T1 (de) Peroxidase-gen von mikrobischem ursprung
EP0048497A3 (en) Dna transducing vector and microorganism containing it
GR78104B (pt)
DE69227661D1 (de) Lineare Plasmide von Pichia pastoris und Fragmente davon
WO1999060140A3 (en) Geminivirus inducible promoter sequences and the uses thereof
HK1084148A1 (en) Mn gene and protein
TH7509A (th) กระบวนการที่ใช้ในการรวมยีนที่เลือกสรรแล้วเข้าเป็นหน่วยเดียวกันกับโครโมโซมของแบคทีเรีย และแบคทีเรียที่ได้จากกระบวนการดังกล่าว
TH7509EX (th) กระบวนการที่ใช้ในการรวมยีนที่เลือกสรรแล้วเข้าเป็นหน่วยเดียวกันกับโครโมโซมของแบคทีเรีย และแบคทีเรียที่ได้จากกระบวนการดังกล่าว
DE48497T1 (de) DNA-Transduktionsvektor und diesen enthaltender Mikroorganismus